SCHEMBL24993400

SCHEMBL24993400

COc1ccc(-c2cncc(C(=O)N/N=C/c3cccc(OC)c3)n2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 4/20 0.63
▸ ALDH1A1 P00352 3/20 0.63
▸ CYP2C19 P33261 3/20 0.63
▸ CYP1A2 P05177 1/20 0.63
▸ GAA P10253 1/20 0.63
▸ MEN1 O00255 2/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ MGAM O43451 1/20 0.55
▸ MAPT P10636 4/20 0.54
▸ HTT P42858 2/20 0.54
▸ KDM4E B2RXH2 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ NPC1 O15118 4/20 0.53
▸ RAB9A P51151 3/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ PKM P14618 1/20 0.52
▸ CYP2D6 P10635 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ CYP3A4 P08684 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29214775 1.00 HPGD (0.63) HPGDALDH1A1CYP2C19CYP1A2GAA
SCHEMBL29215110 0.93 KMT2A (0.56) HPGDALDH1A1CYP2C19CYP1A2GAA
SCHEMBL30925900 0.93 KMT2A (0.56) HPGDALDH1A1CYP2C19CYP1A2GAA
SCHEMBL24993388 0.93 KMT2A (0.56) HPGDALDH1A1CYP2C19CYP1A2GAA
SCHEMBL31026483 0.93 KMT2A (0.57) HPGDALDH1A1CYP2C19CYP1A2GAA
SCHEMBL24993390 0.92 ALDH1A1 (0.55) HPGDALDH1A1CYP2C19CYP1A2GAA
SCHEMBL30925901 0.92 ALDH1A1 (0.57) HPGDALDH1A1CYP2C19CYP1A2GAA
SCHEMBL24993513 0.92 ALDH1A1 (0.57) HPGDALDH1A1CYP2C19CYP1A2GAA
SCHEMBL30925926 0.92 ALDH1A1 (0.55) HPGDALDH1A1CYP2C19CYP1A2GAA
SCHEMBL29214942 0.92 ALDH1A1 (0.57) HPGDALDH1A1CYP2C19CYP1A2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240335442-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS UNIVERSIDADE FEDERAL DO RIO DE JANEIRO – UFRJ (BR) 2024-10-10 — — US claimed
CN-118076348-A N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same 欧罗法玛实验室股份公司 2024-05-24 — — CN claimed
US-20240335442-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS UNIVERSIDADE FEDERAL DO RIO DE JANEIRO – UFRJ (BR) 2024-10-10 — — US disclosed
CN-118076348-A N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same 欧罗法玛实验室股份公司 2024-05-24 — — CN disclosed
WO-2023010191-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS EUROFARMA LABORATÓRIOS S.A. (BR) 2023-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240335442-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS SCN1A, SCN7A, SCN8A HPGD 1380/4885ALDH1A1 320/4885CYP2C19 1440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback